دورية أكاديمية
أعرض في EDS

Treatment of multiple myeloma based on autologous stem cell transplant: An overview of systematic reviews.

التفاصيل البيبلوغرافية
العنوان: Treatment of multiple myeloma based on autologous stem cell transplant: An overview of systematic reviews.
المؤلفون: Liang J; School of Public Health, Zhejiang Chinese Medical University, Hangzhou, P.R. China., Yang Y; The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, P.R. China., He P; School of Public Health, Zhejiang Chinese Medical University, Hangzhou, P.R. China., Mandizadza OO; School of Public Health, Zhejiang Chinese Medical University, Hangzhou, P.R. China., Zhang W; The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, P.R. China., Lin S; The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, P.R. China., Ji C; School of Public Health, Zhejiang Chinese Medical University, Hangzhou, P.R. China.
المصدر: Medicine [Medicine (Baltimore)] 2023 Oct 06; Vol. 102 (40), pp. e35456.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Hematopoietic Stem Cell Transplantation*/methods , Multiple Myeloma*/therapy, Humans ; Research Design ; Survival Rate ; Transplantation, Autologous/methods ; Systematic Reviews as Topic
مستخلص: Background: Multiple myeloma (MM) is a malignant plasma cell disease. In recent years, several systematic reviews, and meta-analyses have been published on treatment protocols, including autologous stem cell transplantation for MM.
Methods: Web of Science, PubMed, Embase, and Cochrane Library were searched to systematically summarize the quality of the methodology and evidence of meta-analyses regarding treatment of MM including autologous stem cell transplantation.
Results: Total 11 meta-analyses were included. The preferred reporting items for systematic reviews and meta-analyses evaluation revealed that the quality of included reviews was affected by possible unevaluated bias between studies and the lack of protocol and registration. The AMSTAR2 scale indicated that the quality of the methodology of included reviews ranged from very low to moderate. The grading, assessment, development, and evaluation of recommendations evaluation showed that among the included outcome indicators, most of them are of low quality.
Conclusion: This overview suggested that the combination of drugs has improved patient survival rates, efficacy and safety compared with the standard regimen. However, the strength of the evidence is uneven and due to methodological errors, the results should be interpreted with caution in order to provide a reference for further improvement of the study design. The methodological quality of the relevant meta-analysis needs to be further improved.
Competing Interests: The authors have no conflicts of interest to disclose.
(Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.)
References: Cullis J. Haematology: multiple myeloma. Clin Med (Lond). 2019;19:188.
Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol. 2016;43:676–81.
Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:548–67.
Joshua DE, Bryant C, Dix C, et al. Biology and therapy of multiple myeloma. Med J Aust. 2019;210:375–80.
Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33.
Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 2006;107:904–6.
Cid Ruzafa J, Merinopoulou E, Baggaley RF, et al. Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model. Pharmacoepidemiol Drug Saf. 2016;25:871–9.
Phekoo KJ, Schey SA, Richards MA, et al. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol. 2004;127:299–304.
Bladé J, Kyle RA, Greipp PR. Multiple myeloma in patients younger than 30 years. Report of 10 cases and review of the literature. Arch Intern Med. 1996;156:1463–8.
Cowan AJ, Allen C, Barac A, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4:1221–7.
Takamatsu H, Honda S, Miyamoto T, et al. Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era. Cancer Sci. 2015;106:179–85.
Morea P, San Miguel J, Sonneveld P, et al. Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv52–61.
Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, et al. Multiple myeloma: role of autologous transplantation. Cancer Treat Rev. 2020;82:101929.
Mahajan S, Tandon N, Kumar S. The evolution of stem-cell transplantation in multiple myeloma. Ther Adv Hematol. 2018;9:123–33.
Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27–38.
Dimopoulos MA, Gay F, Schjesvold F, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2019;393:253–64.
Tzogani K, Penninga E, Schougaard Christiansen ML, et al. EMA review of daratumumab for the treatment of adult patients with multiple myeloma. Oncologist. 2018;23:594–602.
Kapoor P, Rajkumar SV, Dispenzieri A, et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia. 2011;25:689–96.
Thomson D, Russell K, Becker L, et al. The evolution of a new publication type: steps and challenges of producing overviews of reviews. Res Synth Methods. 2010;1:198–211.
Zeng X, Zhang Y, Kwong JSW, et al. The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review. J Evid Based Med. 2015;8:2–10.
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
Brozek JL, Akl EA, Alonso-Coello P, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy. 2009;64:669–77.
Page MJ, Moher D, McKenzie JE. Introduction to PRISMA 2020 and implications for research synthesis methodologists. Res Synth Methods. 2021;13:156–63.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.
Kirmayr M, Quilodrán C, Valente B, et al. The GRADE approach, Part 1: how to assess the certainty of the evidence. Medwave. 2021;21:e8109.
Yang G, Geng C, Jian Y, et al. Triplet RVd induction for transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis. Adv Ther. 2022;39:3799–834.
Dhakal B, Szabo A, Chhabra S, et al. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis. JAMA Oncol. 2018;4:343–50.
Al-Ani F, Louzada M. Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone in multiple myeloma: a systematic review. Eur J Haematol. 2017;99:479–88.
Teh BW, Harrison SJ, Worth LJ, et al. Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: a systematic review and meta-analysis. Eur J Cancer. 2016;67:21–37.
Leiba M, Kedmi M, Duek A, et al. Bortezomib-cyclophosphamide-dexamethasone (VCD) versus bortezomib-thalidomide-dexamethasone (VTD) -based regimens as induction therapies in newly diagnosed transplant eligible patients with multiple myeloma: a meta-analysis. Br J Haematol. 2014;166:702–10.
Zou Y, Sheng Z, Niu S, et al. Lenalidomide versus thalidomide based regimens as first-line therapy for patients with multiple myeloma. Leuk Lymphoma. 2013;54:2219–25.
Zou Y, Sheng Z, Lu H, et al. Continuous treatment with new agents for newly diagnosed multiple myeloma. Anticancer Drugs. 2013;24:527–33.
Mian H, Mian OS, Rochwerg B, et al. Autologous stem cell transplant in older patients (age ≥ 65) with newly diagnosed multiple myeloma: a systematic review and meta-analysis. J Geriatr Oncol. 2020;11:93–9.
Jain T, Sonbol MB, Firwana B, et al. High-dose chemotherapy with early autologous stem cell transplantation compared to standard dose chemotherapy or delayed transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2019;25:239–47.
Kumar A, Kharfan-Dabaja MA, Glasmacher A, et al. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst. 2009;101:100–6.
Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007;13:183–96.
Bigby M. Understanding and evaluating systematic reviews and meta-analyses. Indian J Dermatol. 2014;59:134–9.
Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021;5:e528.
Bobin A, Liuu E, Moya N, et al. Multiple myeloma: an overview of the current and novel therapeutic approaches in 2020. Cancers (Basel). 2020;12:2885.
تواريخ الأحداث: Date Created: 20231006 Date Completed: 20231010 Latest Revision: 20231107
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC10553094
DOI: 10.1097/MD.0000000000035456
PMID: 37800752
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-5964
DOI:10.1097/MD.0000000000035456